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NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis,
ameliorates interleukin 2-induced capillary leakage and reduces tumour
growth in adenocarcinoma-bearing mice
A Orucevic and PK Lala
Department ofAnatomy, The University of Western Ontario, London, Ontario, N6A SCJ, Canada.
Summary We tested whether NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO)
synthesis, can prevent interleukin 2 (IL-2)-induced capillary leakage in tumour-bearing mice without
compromising the therapeutic benefits of IL-2. C3H/HeJ female mice transplanted s.c. with 2.5 x 105 C3-L5
mammary carcinoma cells were treated with: nothing, IL-2 (ten injections of 15 000 Cetus units i.p. every 8 h),
L-NAME (0.1, 0.5, or 1 mg ml-1 drinking water), IL-2+L-NAME (0.1 or 0.5 or 1 mg ml-' drinking water).
Therapies were given in one round (IL-2, days 10-13; L-NAME, days 9-13) or in two rounds (IL-2, days 10-
13 and 20-23; L-NAME, days 9-13 and days 19-23) after tumour transplantation. Capillary leakage was
measured from the water contents of the pleural cavities, lungs, spleen and kidneys. Effects of the therapies on
the primary tumour size and the number of spontaneous lung metastases were also recorded. NO production
was measured as the nitrite+nitrate levels in the serum and in the pleural effusion. After the first round of
therapies, addition of L-NAME significantly reduced IL-2-induced pulmonary oedema and water retention in
the spleen in a dose-dependent manner. It also significantly reduced the IL-2-induced rise in NO levels in the
serum and pleural fluid, but did not affect IL-2-induced pleural effusion or water retention in the kidney. At
later stages of tumour growth (day 23), tumours themselves induced significant fluid retention in the lungs and
the kidney, which was not aggravated further with the second round of IL-2 therapy. At this time, L-NAME
therapy alone ameliorated tumour-induced pulmonary oedema. During both rounds of therapy different doses
of L-NAME alone caused a reduction ofprimary tumour growth as well as spontaneous lung metastases, which
improved further with the addition of IL-2. The combination therapy was at least as effective as IL-2 therapy.
In summary, L-NAME had anti-tumour effects in vivo, reduced the severity of IL-2-induced capillary leakage in
some organs and did not compromise anti-tumour efficacy of IL-2 therapy. Thus, L-NAME could be a valuable
adjunct to IL-2-based cancer therapy.
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Interleukin 2 (IL-2) therapy, alone or in combination with ex
vivo-generated lymphokine-activated killer (LAK) cells, can
cause tumour regression in mice (Rosenberg et al., 1985;
Ettinghausen et al., 1988) and in man (Rosenberg, 1989;
Fisher et al., 1988; Dutcher et al., 1989; Parkinson et al.,
1990). Widespread clinical use of IL-2 has been limited by the
low rate of complete remission and by severe toxicity (Hibbs
et al., 1992; Siegel and Puri, 1991). Capillary leak syndrome
is a major side-effect of high-dose IL-2 therapy, characterised
by retention of extravascular fluid and hypotension (Siegel
and Puri, 1991). It has been observed in humans (Siegel and
Puri, 1991; Margolin et al., 1989; Rosenberg et al., 1987) as
well as in mice (Rosenstein et al., 1986).
A number of in vitro as well as in vivo observations suggest
that IL-2-induced capillary leakage may result from multiple
mechanisms: damage to endothelial cells by LAK cells and
natural killer (NK) cells (Amador et al., 1991; Aronson et al.,
1988); a direct injury to endothelial cells inflicted by two
cytokines induced by IL-2 therapy - interferon (IFN)y
(Montesano et al., 1985) and tumour necrosis factor (TNF)-ca
(Kahaleh et al., 1988); and finally, vasodilation due to IL-2-
induced production of nitric oxide (NO) (Hibbs et al., 1992;
Ochoa et al., 1992), leading to systemic hypotension followed
by pulmonary hypertension and oedema.
There have been several reports of therapies that combine
IL-2 with agents that might ameliorate the capillary leakage.
However, the added drugs also opposed the anti-tumour
effects of IL-2. Corticosteroids (Rosenstein et al., 1986;
Faggioni et al., 1994), which suppress inflammatory and
immune responses as well as production of NO (Moncada
and Higgs, 1993), and asialo-GM-1 antibody, which depletes
LAK cells (Ettinghausen et al., 1988), both fall into this
category. Puri et al. (1989) have reported that IL-la reduced
IL-2-induced capillary leakage but did not improve animal
survival. Welbourn et al. (1991) reported that certain
cyclopeptides, e.g. antamanide and phalloidine, reduced IL-
2-induced oedema in the rat, presumably by causing
cytoskeletal changes in neutrophils, with consequent suppres-
sion of endothelial injury by thromboxane B2. Interactions of
these agents with the anti-tumour effect of IL-2 remain
unknown. Further studies are therefore required to identify
substances that can ameliorate capillary leakage without
reducing the anti-tumour effects of IL-2.
Severe hypotension observed during IL-2 therapy has been
recently attributed to the production of NO from L-arginine
(Hibbs et al., 1992; Ochoa et al., 1992), indicating the
potential value of NO synthase inhibitors in preventing IL-2-
induced hypotension. This prompted our studies with two
NO synthase inhibitors. We found that one such inhibitor,
N0-methyl-L-arginine (NMMA) failed to ameliorate IL-2-
induced capillary leakage, but improved anti-tumour effect of
IL-2 in mice (Orucevic and Lala, 1992, 1993). Subsequently,
we discovered that NG-nitro-L-arginine methyl ester (L-
NAME; a more potent NO synthase inhibitor) given orally
could effectively prevent capillary leakage induced by IL-2 in
healthy mice (Orucevic and Lala, 1995a).
The objectives of the present study were to examine
whether L-NAME can prevent IL-2-induced capillary leakage
in tumour-bearing mice without compromising the therapeu-
tic benefit of IL-2.
Materials and methods
Mice
C3H/HeJ female mice, 6-7 weeks old, were obtained from
the Jackson Laboratories (Bar Harbor, ME, USA). Animal
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care was in accord with guidelines of the Canadian Council
on Animal Care. Mice were kept on a 12 h light/dark cycle,
fed with a standard mouse chow and provided with water ad
libitum.
Interleukin 2
Highly purified recombinant human IL-2 (lot LQP-046) was
kindly provided by Chiron Corp (Emeryville, CA, USA). The
sp. act. was 18 x 106 International units mg-1 or 3 x 106 Cetus
units mg-1 IL-2. The lyophilised IL-2 (1.2 mg per vial) was
first reconstituted with 1 ml of distilled water and further
diluted with RPMI-1640 medium (ICN Biomedicals, Costa
Messa, CA, USA) in order to obtain the concentration of
15 000 Cetus units in 0.1 ml (volume per injection). The
reconstituted IL-2 was stored at 4°C for up to 1 day.
NG-nitro-L-arginine methyl ester
L-NAME (Sigma, St Louis, MO, USA) was added to the
drinking water to provide concentrations of 0.1, 0.5 and
1 mg ml-' of water. These doses were based on our studies
conducted earlier to prevent IL-2-induced capillary leak
syndrome in healthy mice (Orucevic and Lala, 1994, 1995a).
In one additional experiment, we investigated the effects of
the D-form of NAME (D-NAME; 1 mg ml-' of water;
obtained also from Sigma) in order to evaluate the specificity
of L-NAME action, since D-NAME is incapable of inhibiting
NO synthase (Ialenti et al., 1993).
Tumour-cell line
A spontaneous mammary tumour in a C3H/HeJ mouse,
which also exhibited lung metastases (Brodt et al., 1985), was
the source of a primary transplantable tumour, T58, from
which the metastatic C3 line had been clonally derived (Lala
et al., 1986). Since the spontaneous lung metastatic ability of
the C3 line declined after in vitro passages over the years
(Lala et al., 1986), a highly metastatic C3-L5 line was derived
from the C3 line by five cycles of in vivo selection for
spontaneous lung metastasis (Lala and Parhar, 1993) as
follows. C3 cells were transplanted s.c. into C3H/HeJ mice
and allowed to metastasise to the lungs. Cells from the lung
micrometastases were then injected s.c. into fresh C3H/HeJ
recipients, and again allowed to metastasise to the lungs. This
cycle was repeated five times. The C3-L5 line has since
maintained its strong metastatic phenotype both in C3H/
HeN (Saarloos et al., 1992) and C3H/HeJ (Lala and Parhar,
1993) strains of mice.
Tumour transplantation
C3-L5 mammary adenocarcinoma cells (2.5 x 105 in 0.1 ml of
RPMI medium) were injected s.c. in the mammary line near
the axilla. In addition to the formation of primary tumours,
this procedure was expected to produce micrometastases in
the lungs of C3H/HeJ mice within 10 days of transplantation
(Lala and Parhar, 1993).
Protocols for immunotherapy
Tumour transplanted mice, randomly separated into eight
groups (n = 10-20), were treated with: nothing, IL-2 (ten
injections of 15 000 Cetus U i.p. every 8 h), L-NAME
(0.1 mg ml- drinking water), L-NAME (0.5 mg ml-1 drink-
ing water), L-NAME (1 mg ml-' drinking water), IL-
2+0.1 mg ml-' L-NAME, IL-2+0.5 mg ml 1 L-NAME,
IL-2 + 1 mg ml-' L-NAME. Therapies were given in one
round (IL-2, days 10-13; L-NAME, days 9-13), or in two
rounds (IL-2, days 10-13 and 20-23; L-NAME, days 9-13
and days 19-23) after tumour transplantation. In one
additional experiment, mice (n=5) were treated with IL-2
or IL-2 + 1 mg ml-' D-NAME (IL-2, days 10-13; D-NAME,
days 9-13). Mice were killed after one or two rounds of
treatments (1 h after last IL-2 injection) to measure capillary
leakage and anti-tumour effects of therapies. Some animals
succumbed to IL-2 toxicity after the first round of IL-2, so
that all animals did not survive to the beginning of the
second round. Autopsy was performed on all dead animals
and the quantity of pleural effusion was measured.
Measurement of capillary leakage and NO metabolites
The left lung, the spleen and the left kidney were recovered
for measurement oftheir water content. The wet weights were
recorded, then the organs were frozen (-80°) and freeze
dried to constant weight. Water content of each organ was
expressed as wet-dry weight ratio.
The volume of liquid from both pleural cavities was
measured directly by complete aspiration with a 1 ml syringe
as follows. After removing the skin, the anterior thoracic wall
was cut at three levels: inferior to the sternum, and at both
anterior axillary lines, so that it could be lifted without
severing major blood vessels of the thoracic wall or the
mediastinum. Both costodiaphragmatic recesses were then
accessed with a syringe. This procedure allowed collection of
blood-free aspirates. On rare occasions of blood contamina-
tion, the samples were excluded from the study.
Samples of serum and pleural effusion were collected after
the first or second round of treatments to measure NO2- and
NO3-, the principal metabolites of NO (Moncada and Higgs,
1993; Kelm et al., 1992). Griess reagent (Green et al., 1982)
was used for measurement of NO2- and cadmium filings for
conversion of NO3- to NO2- (Davison and Woof, 1978).
Measurement of anti-tumour effects
The size of the primary tumours was measured with callipers
on days 9, 14, 19 and 23, by recording the maximum and
minimum diameters. Tumour volumes were then calculated
as 0.52a2b, where a and b are the minimum and maximum
diameters (Baguley et al., 1989), and the tumour volume
represented in mm3.
The right lung was isolated and fixed with Bouin's fixative.
The number of metastatic nodules in the lungs was scored
using a dissecting microscope.
Statistical analysis
The Microstat statistics package (Ecosoft, Indianapolis, IN,
USA) was used in the analysis of collected data. One-way
ANOVA was used for normal distributions and the Kruskal-
Wallis test for non-normal distributions. Newman - Keuls
test and non-parametric multiple range test were respectively
used to determine which means or sums of ranks differed
significantly (P<0.05) from one another (Zar, 1974).
Results
Effects of L-NAME on IL-2-induced capillary leakage after
one or two rounds of therapies
A single round of IL-2 therapy induced a significant amount
of pleural effusion. This was 0.38+0.05 ml in animals that
were killed immediately after the first round of therapy, and
0.92+0.07 ml in animals that died within 5 days after the
first round of therapy. The reduction of IL-2-induced pleural
effusion noted in either group was not significant with the
addition of different doses (0.1, 0.5 and 1 mg ml-') of L-
NAME (data not presented). There was no detectable pleural
effusion after the second round of therapies inclusive of IL-2.
L-NAME therapy alone did not induce pleural effusion in
any of the animals (data not shown).
Addition of various doses of L-NAME significantly
(P<0.05) reduced IL-2-induced pulmonary oedema after
the first round of therapies (Figure la). At the time of
completion of the second round of therapy (day 23),
untreated tumour-bearing mice showed a higher water
content in the lungs as compared with healthy animals.
This was not aggravated further by IL-2 therapy. Thetumour-induced water retention in the lungs was significantly
ameliorated only by L-NAME therapy alone (P<0.01)
(Figure Ib).
IL-2-induced water retention in the spleen decreased
significantly (P<0.001) with addition of L-NAME in a
dose-dependent manner after the first round of therapies
(Figure 2a). After the second round of therapies, different
doses of L-NAME did not significantly influence IL-2-
induced water retention in the spleen (Figure 2b). L-NAME
therapy alone did not have any effect on the water content in
the spleen after the first or the second round of therapy
(Figure 2).
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After the first or the second round of therapy, IL-2-
induced fluid retention in the kidney remained unaffected
with addition of any of the L-NAME doses (Figure 3).
Tumour-bearing by itself induced a significant increase in the
water content in the kidney (Figure 3), which was
significantly (P<0.05) reduced by L-NAME therapy alone,
but only after the first round of therapy (Figure 3).
Effects of therapies on animal morbidity
After the first round of treatments, some tumour-trans-
planted animals died from IL-2-induced toxicity in all IL-2
treated groups. There was no death due to tumour-
transplantation at this time. The reduction of IL-2-induced
mortality by the addition of various doses of L-NAME
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Figure 1 Water content in the lungs after one (a) or two (b)
rounds of IL-2 and L-NAME therapy. Data represent mean+s.e.
(a) n = 10. (b) n =9-12. *Addition of L-NAME significantly
(P<0.05) reduced IL-2-induced pulmonary oedema after the first
round oftherapies. tTumour bearing by itself at a time coinciding
with the end of the second round of therapies, induced a
significant (P<0.05) increase in the water content in the lungs.
tL-NAME therapy significantly (P<0.01) reduced tumour-
induced water retention in the lungs.
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Figure 2 Water content in the spleen after one (a) or two (b)
rounds of IL-2 and L-NAME therapy. Data represent mean+s.e.
(a) n=10. (b) n=9-12. *Addition of L-NAME significantly
(P<0.001) decreased IL-2-induced water retention in the spleen in
a dose-dependent manner after the first round of therapies.
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pleural effusion in tumour-bearing mice after the first round
of therapies (Figure 4). After the second round, IL-2 therapy
did not influence NO2 +NO3- levels in the serum of these
animals, while addition of 1 mg ml-' L-NAME to IL-2
significantly increased these levels (Figure 4b). L-NAME
therapy alone did not have any effect on NO2- +NO3- levels
in the serum measured after the first or the second round
(Figure 4a and b).
Effects of L-NAME and IL-2 therapy on the primary tumour
size and number of lung metastatic nodules
All forms of therapy (L-NAME alone at various doses, IL-2
alone or IL-2+ L-NAME) significantly (P<0.05) reduced the
growth of primary tumours. The best responses were seen
with L-NAME alone at 1 mg ml-', IL-2 alone or IL-2+L-
NAME (at various doses) (Figure 5). Addition of L-NAME
to IL-2 therapy had only a transient (noted on day 14, at the
end of the first round) beneficial effect on primary tumour
growth (Figure 5), which was reproduced in another
experiment (data not shown).
All therapies, except 1 mg ml-' L-NAME alone, signifi-
cantly reduced the number of lung metastatic nodules.
Reduction with IL-2 alone or IL-2 in combination with L-
NAME was greater than with L-NAME alone (Figure 6).
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Figure 3 Water content in the kidney after one (a) or two (b)
rounds of IL-2 and L-NAME therapy. Data represent mean+s.e.
(a) n =10. (b) n=9-12. *Tumour-bearing by itself induced an
early, day 13 (a) and sustained, day 23 (b), increase in the water
content in the kidney (P<0.05). fL-NAME therapy alone
significantly (P<0.05) decreased tumour-induced fluid retention
in the kidney after the first round of therapy.
therapy was not significant. L-NAME therapy alone at any
dose level did not cause any mortality in healthy or tumour-
transplanted mice (data not presented).
Effects of L-NAME and IL-2 therapy on NO2- +NO3- levels
in the serum andpleural effusion
The basal concentrations of NO2- in the serum and pleural
effusion were not detectable, since they were below the
sensitivity of the assay (<1I M). NO2- levels shown in
Figure 4 were obtained by reducing NO3- to NO2- with
cadmium filings and thus represent NO2- +NO3- levels.
Different doses of L-NAME significantly reduced IL-2-
induced increases in NO2-+NO3- levels in the serum and
Effects of D-NAME on IL-2-induced capillary leakage, NO
production and anti-tumour effects
NG-nitro-D-arginine methyl ester (D-NAME) (1 mg ml-') had
no significant effect on IL-2-induced pleural effusion, rise in
water content in the spleen and kidney, or the reduction of
the primary tumour size after the first round of therapies
(n=5 per group, data not presented). Furthermore, D-NAME
had no influence on IL-2-induced rise in the levels of
NO2- +NO3- in the serum and pleural effusion of the
tumour-bearing mice after one round of therapies (data not
presented). However, there was a minor reduction in IL-2-
induced pulmonary oedema caused by addition of D-NAME.
D-NAME alone (1 mg ml-') had no effect on the growth of
the primary tumour (data not shown).
Discussion
The results of the present study showed that oral
administration of L-NAME, a potent inhibitor of NO
synthesis, reduced the severity of IL-2-induced capillary
leakage in some organs of tumour-bearing mice, without
compromising the therapeutic benefits of IL-2. Furthermore,
L-NAME therapy alone had significant anti-tumour effects.
We demonstrated that IL-2-induced pulmonary oedema,
water retention in the spleen and rise in nitrite+nitrate levels
(in the serum and pleural effusion) after the first round of
therapy were all significantly reduced with addition of L-
NAME. However, this addition did not affect the level of IL-
2-induced pleural effusion or water retention in the kidney
after one round of therapy. These results in tumour-
transplanted mice are in general accord with those
previously reported by us in healthy mice (Orucevic and
Lala, 1995a). In both of these studies, two lines of evidence
excluded the possibility that the therapeutic effects of L-
NAME in reducing the water content ofcertain organs in IL-
2-treated mice were due to L-NAME-induced reduction in
water consumption (antidypsogenic effect): (1) we noted that
higher doses of L-NAME (eg. 1 mg ml-'), as well as the
present dose of IL-2 led to a significant reduction in water
consumption (up to 60% ofpretreatment values at the end of
the first round of therapy). However, the water consumption
in IL-2-treated mice remained unaffected by the addition of
L-NAME; (2) In spite of antidypsogenic effects, L-NAME
therapy alone did not influence the water content of any
organ in healthy mice. Furthermore, L-NAME is well
recognised for its vasoconstrictive effects in healthy animals
(Gross et al., 1990). Since this effect alone did not influence
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Figure 4 NO3- levels in the serum (a) after one round of
therapy (b) after two rounds of therapy; and (c) pleural effusion
after one round of therapy, measured as NO2- after reduction.
Data represent mean+ s.e. (n =3 -5, each done in duplicate).
*Dose-dependent trend in reduction of NO3- levels in the serum
with addition of different doses of L-NAME to IL-2 after the first
round of therapy. tOnly the dose of 1 mgml- 1 L-NAME caused
Time after tumour transplantation (days)
Figure 5 Growth of the primary tumour during IL-2 and L-
NAME therapy, as given by the mean tumour volume on days 9,
14, 19 and 23. Data represent mean+s.e. (days 9 and 14: n= 10-
20; day 19 and day 23: n=9-12). After the first (day 14) or the
second round (day 23) oftherapies, IL-2 alone, or in combination
with any dose of L-NAME, or L-NAME alone significantly
(P<0.05) reduced the growth of the primary tumour. 0, Tumour
control; 0, 0.l mgml- L-NAME; V, 0.5mgml-l L-NAME; V,
ImgmI-l L-NAME; O], IL-2; *, IL-2+0.1 mgmI - L-NAME;
A, IL-2 +0.5mgmI- V L-NAME; A, IL-2+ 1 mgml-V L-NAME.
the water content of any organ in healthy mice treated with
L-NAME alone, the observed L-NAME-induced reduction of
water content ofthe lungs and the spleen in IL-2-treated mice
cannot be explained solely on the basis of generalised or
selective vasoconstriction of normal vascular beds.
We suggest that the beneficial effects of L-NAME against
IL-2-induced capillary leakage resulted from an abrogation of
IL-2-induced NO overproduction (measured in the serum and
pleural fluid) documented here, as well as in healthy tumour-
free mice (Orucevic and Lala, 1995a). This abrogation
occurred in spite of reported higher selectivity of L-NAME
for binding and inactivation of the constitutive isoforms of
NO synthase (NOS) enzymes in comparison with the
inducible isoform (i-NOS) (Gross et al., 1990; Dwyer et al.,
1991; Furfine et al., 1993). For these reasons, further
investigation is needed to identify the cellular source of NO
as well as the NOS isoform(s) responsible for increased NO
production after IL-2 therapy. This information may also
indicate the relative contribution of haemodynamic (owing to
eNOS) and other effects (owing to iNOS) of NO towards IL-
2-induced capillary leakage.
At later stages of tumour growth (day 23), tumours
themselves induced significant fluid retention in the lungs and
the kidney, and the former was reduced with L-NAME
therapy alone. It is likely that the increased fluid retention in
the lungs was a direct result of pulmonary metastases due to
either an increased leakiness of the capillaries supplying the
metastatic foci, or an increased leakiness of the lung
vasculature in the presence of metastasis. Thus a reduction
in tumour-induced pulmonary oedema can be explained by
the anti-metastatic effects of L-NAME (documented here)
and/or a selective reduction in tumour blood flow (Andrade
et al., 1992) within the metastatic foci. IL-2 therapy alone, in
spite of strong anti-metastatic effects, failed to reduce the
significant (P<0.05) abrogation of IL-2-induced rise in N03-
levels in the serum after the first round of therapies. tAddition
of mgmI- L-NAME to IL-2 significantly (P<0.05) increased
NO3- levels in the serum after the second round of therapies.
§ IL-2-induced NO production in pleural effusion after the first
round of therapy was significantly (P<0.05) reduced with
addition of L-NAME.
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Figure 6 Number of metastatic nodules in the lungs scored on
day 23 after two rounds of IL-2 and L-NAME therapy (n=9-
12). *Significant reduction (P<0.05) was noted with all therapies
except with 1 mgml- 1 L-NAME. C], mean+ s.e.; *, median.
water content of the lungs, probably because of additional
IL-2-induced pulmonary oedema.
A second round of IL-2 therapy caused a milder degree of
capillary leakage (fluid retention in the spleen, but not the
lungs, kidney or the pleural cavities), which was not
ameliorated by addition of L-NAME. In parallel, there was
no significant change in NO production in most groups
receiving IL-2 or the combination therapy. While this
association may reinforce the role of NO in IL-2-induced
capillary leakage, the reasons for a resistance of healthy mice
(Orucevic and Lala, 1995b) as well as tumour-bearing mice
(this study) to the induction of pleural effusion by the second
round of IL-2 remains unclear. Identification and cellular
localisation of NOS isoforms in the treated mice may resolve
this issue. The expression of iNOS is known to vary from
tissue to tissue and within a given tissue under different
circumstances (Nussler and Billiar, 1993). Thus, it is possible
that our second round of IL-2 did not induce iNOS in the
pleural vessels, which consequently remained resistant to
leakage. The so called 'tolerance' to IL-2 toxicity after the
initial round reported by our laboratory in the human
(Mertens et al., 1993) and a milder fall in blood pressure after
the second course of IL-2 reported by another laboratory
(Hibbs et al., 1992) might be similarly explained.
We found that anti-tumour effects of IL-2 were not
compromised with addition of L-NAME and that L-NAME
therapy alone had anti-tumour effects. These findings were
similar to our previous observations with another NOS
inhibitor, NMMA (Orucevic and Lala, 1993). The observed
anti-tumour effects of NOS inhibitors in our tumour model
are in accord with those documented in a rat model
(Kennovin et al., 1993, 1994).
Mechanisms responsible for the anti-tumour effects of
NOS inhibitors in the present as well as other studies remain
to be fully investigated. They may include a reduction in the
tumour blood flow, tumour angiogenesis, tumour invasive-
ness and an abrogation of NO-induced immunosuppression
in the host. Evidence exists for some of the above. Kennovin
et al. (1993, 1994) observed that the anti-tumour effects were
not sustained after withdrawal of chronic L-NAME therapy
of tumour-bearing rats. For this and other reasons, they
postulated that the therapeutic effects were probably due to a
reduction in tumour blood flow, caused by a selective
constriction of the tumour vasculature owing to an
inhibition of iNOS activity. Indeed, NO production by
experiment tumours in mice has been implicated in
maintaining tumour blood flow in the neovasculature
(Buttery et al., 1993), and its blockade with L-NAME has
been shown to selectively reduce flow in tumour-associated
neovasculature (Andrade et al., 1992) and to cause a severe
tumour hypoxia (Wood et al., 1993).
There is a growing number of reports on the opposing
roles of NO on the immune system that may influence
tumour growth. While NO may be required for tumoricidal
function ofcertain effector cells, excessive NO production can
also suppress lymphocyte activation. It has been shown that
activated murine macrophages synthesise NO from L-arginine
(Stuehr and Marletta, 1985), which may partly mediate the
cytotoxic activity of these cells against tumour cells and
bacteria (Lancaster and Hibbs, 1990). Mills et al. (1992)
reported that tumour growth in the peritoneal cavity of mice
was associated with a marked decline in the production of
NO by intra-tumour macrophages. On the other hand,
murine macrophages have been shown to down-regulate
lymphocyte activation by an NO-dependent mechanism
(Hoffman et al., 1990; Albina et al., 1991), which may
compromise the tumoricidal function of lymphocytes. Indeed,
NO has been implicated in the tumour-induced immunosup-
pression in rats (Lejeune et al., 1994) and high NO synthase
activity has been correlated with the degree of malignancy
(Thomsen et al., 1994).
In a preliminary study (A Orucevic and PK Lala,
unpublished), we found an improvement in IL-2-induced
LAK cell function in vivo with addition of L-NAME in
tumour-bearing mice after the first round of therapy. This
may explain our findings of a transient improvement of IL-2-
induced retardation of tumour growth by addition of L-
NAME after the first round of therapy (present study).
Although L-NAME alone did not significantly change serum
levels of nitrite+nitrate, we demonstrated that L-NAME-
mediated reduction of tumour size was related to NO
pathway, since treatment of mice with D-NAME, an amino
acid incapable of inhibition of NO generation (lalenti et al.,
1993), failed to influence tumour growth rate (data not
shown). We are currently investigating the identity of the
NOS isoforms and the cellular source of NO in our tumour
model.
In summary, L-NAME therapy had an anti-tumour effect
when given alone. In combination with IL-2, L-NAME
reduced the severity of IL-2-induced capillary leakage in
some organs after the first round of therapy and did not
compromise anti-tumour effects of IL-2 therapy. Thus, L-
NAME could be a valuable adjunct to IL-2-based
immunotherapy of cancer.
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